CAS 15140-27-9: Estra-1,3,5(10)-triene-3,17-diol (17β)-, 17-cyclohexanecarboxylate

Estradiol hexahydrobenzoate is a synthetic estrogen ester, which is meticulously derived from estradiol, a principal endogenous estrogen in humans. As an ester, its structure is modified to enhance its pharmacokinetic profile, allowing for slower release and extended duration of action when administered intramuscularly. This chemical modification optimizes its bioavailability versus pure estradiol, providing a more stable and predictable hormonal effect over time. In terms of mode of action, estradiol hexahydrobenzoate acts by binding to estrogen receptors distributed throughout various tissues, ultimately promoting transcriptional activation or repression according to tissue type. This interaction leads to pronounced physiological changes, such as regulation of the menstrual cycle, promotion of reproductive organ development, and modulation of secondary sexual characteristics. The primary applications of estradiol hexahydrobenzoate consist of hormone replacement therapies (HRT), particularly for alleviating symptoms of menopause, such as hot flashes and osteoporosis, and in certain cases of estrogen deficiency. It's also utilized in transgender hormone therapy to induce feminization. Given its long-acting nature, it offers advantages in maintaining steady hormone levels, thereby improving patient compliance in clinical settings.